{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:41:22Z","timestamp":1778661682660,"version":"3.51.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81774321"],"award-info":[{"award-number":["81774321"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81473777"],"award-info":[{"award-number":["81473777"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Although calcitonin gene-related peptide antagonists and botulinum toxin A have been shown efficacy in preventing chronic migraine, there is no direct evidence for their comparative effectiveness. This review is to assess the comparative effectiveness and safety of calcitonin gene-related peptide antagonists and botulinum toxin A for chronic migraine using network meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>OVID MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials will be searched for relevant randomized controlled trials from their inception to December 2019 without language restriction. We will include trials testing the effectiveness of calcitonin gene-related peptide antagonists or botulinum toxin A in patients with chronic migraine. The outcomes are mean change from baseline in the number of headache days, the mean change from baseline in the number of migraine days, the mean change from baseline in headache hours, responder rate, and adverse events rate. The methodological quality of the included randomized controlled trials will be evaluated using Cochrane Collaboration's risk of bias tool. Standardized mean difference will be used to synthesize continuous variables and risk ratio will be used to synthesize categorical variables. Pairwise and network meta-analysis will be performed using a frequentist method in netmeta package (R 3.5.0, www.r-project.org).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Ethical approval and informed consent are not required for this systematic review. The results will be submitted to a peer-reviewed journal and conference abstracts for publication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The result of the review will systematically provide suggestions for clinicians, patients, and policy makers in the treatment of chronic migraine.<\/jats:p>\n            <jats:p>PROSPERO registration number: CRD42018089201.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000018929","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T02:31:13Z","timestamp":1580351473000},"page":"e18929","source":"Crossref","is-referenced-by-count":5,"title":["Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis"],"prefix":"10.1097","volume":"99","author":[{"given":"Tianwei","family":"She","sequence":"first","affiliation":[{"name":"The Third Hospital\/Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyao","family":"Chen","sequence":"additional","affiliation":[{"name":"The Third Hospital\/Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichun","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Anorectal Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Anorectal Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[{"name":"The Third Hospital\/Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,1]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"g1416","DOI":"10.1136\/bmj.g1416","article-title":"Chronic migraine","volume":"348","author":"Schwedt","year":"2014","journal-title":"BMJ"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","volume":"30","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"key":"R4-20230915","first-page":"CD011616","article-title":"Botulinum toxins for the prevention of migraine in adults","volume":"6","author":"Herd","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","article-title":"Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom","volume":"19","author":"Vo","year":"2018","journal-title":"J Headache Pain"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/0333102413477736","article-title":"Global perspectives on the burden of episodic and chronic migraine","volume":"33","author":"Buse","year":"2013","journal-title":"Cephalalgia"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0333102412468668","article-title":"Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan","volume":"33","author":"Wang","year":"2013","journal-title":"Cephalalgia"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet (London, England)"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756285616677005","article-title":"Botulinum toxin in the management of chronic migraine: clinical evidence and experience","volume":"10","author":"Escher","year":"2017","journal-title":"Therap Adv Neurol Disord"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","article-title":"Migraine\u2013current understanding and treatment","volume":"346","author":"Goadsby","year":"2002","journal-title":"N Engl J Med"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxin A in chronic migraine: a consensus statement from the European Headache Federation","volume":"19","author":"Bendtsen","year":"2018","journal-title":"J Headache Pain"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ane.12906","article-title":"Botulinum toxin: a review of the mode of action in migraine","volume":"137","author":"Do","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the trigeminal system in migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11916-019-0768-y","article-title":"CGRP antagonists for the treatment of chronic migraines: a comprehensive review","volume":"23","author":"Urits","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"R16-20230915","first-page":"10","article-title":"Aimovig for migraine prevention: the new kid may have trouble fitting in","volume":"27","author":"Reinke","year":"2018","journal-title":"Manag Care"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/head.13417","article-title":"Anti-calcitonin gene-related peptide (CGRP) therapies: update on a previous review after the American Headache Society 60th Scientific Meeting, San Francisco, June 2018","volume":"58 Suppl 3","author":"Tepper","year":"2018","journal-title":"Headache"},{"key":"R18-20230915","first-page":"929","article-title":"FDA approves licensing of erenumab-aooe to prevent migraine","volume":"75","author":"Traynor","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:50:10Z","timestamp":1694821810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018929"}},"subtitle":["A protocol for systematic review"],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018929","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}